Cargando…
Locally acting ACE‐083 increases muscle volume in healthy volunteers
Introduction: ACE‐083 is a locally acting follistatin‐based therapeutic that binds myostatin and other muscle regulators and has been shown to increase muscle mass and force in neuromuscular disease mouse models. This first‐in‐human study examined these effects. Methods: In this phase 1, randomized,...
Autores principales: | Glasser, Chad E., Gartner, Michael R., Wilson, Dawn, Miller, Barry, Sherman, Matthew L., Attie, Kenneth M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969095/ https://www.ncbi.nlm.nih.gov/pubmed/29486514 http://dx.doi.org/10.1002/mus.26113 |
Ejemplares similares
-
A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers
por: Attie, Kenneth M, et al.
Publicado: (2014) -
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy
por: Statland, Jeffrey M., et al.
Publicado: (2022) -
Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease
por: Pearsall, R. S., et al.
Publicado: (2019) -
SAT-LB083 Pituitary Apoplexy: What a Headache!
por: Perez Garcia, Yanet, et al.
Publicado: (2019) -
Postprandial dynamics of splenic volume in healthy volunteers
por: Garnitschnig, Lydia, et al.
Publicado: (2020)